249 related articles for article (PubMed ID: 26826008)
1. Dose-dependent inhibition of GCPII to prevent and treat cognitive impairment in the EAE model of multiple sclerosis.
Hollinger KR; Alt J; Riehm AM; Slusher BS; Kaplin AI
Brain Res; 2016 Mar; 1635():105-12. PubMed ID: 26826008
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of glutamate carboxypeptidase II (GCPII) activity as a treatment for cognitive impairment in multiple sclerosis.
Rahn KA; Watkins CC; Alt J; Rais R; Stathis M; Grishkan I; Crainiceau CM; Pomper MG; Rojas C; Pletnikov MV; Calabresi PA; Brandt J; Barker PB; Slusher BS; Kaplin AI
Proc Natl Acad Sci U S A; 2012 Dec; 109(49):20101-6. PubMed ID: 23169655
[TBL] [Abstract][Full Text] [Related]
3. Blocking glutamate carboxypeptidase II inhibits glutamate excitotoxicity and regulates immune responses in experimental autoimmune encephalomyelitis.
Ha D; Bing SJ; Ahn G; Kim J; Cho J; Kim A; Herath KH; Yu HS; Jo SA; Cho IH; Jee Y
FEBS J; 2016 Sep; 283(18):3438-56. PubMed ID: 27444540
[TBL] [Abstract][Full Text] [Related]
4. Dendrimer-2PMPA selectively blocks upregulated microglial GCPII activity and improves cognition in a mouse model of multiple sclerosis.
Hollinger KR; Sharma A; Tallon C; Lovell L; Thomas AG; Zhu X; Wiseman R; Wu Y; Kambhampati SP; Liaw K; Sharma R; Rojas C; Rais R; Kannan S; Kannan RM; Slusher BS
Nanotheranostics; 2022; 6(2):126-142. PubMed ID: 34976589
[TBL] [Abstract][Full Text] [Related]
5. Glutamate carboxypeptidase II (GCPII) inhibitor 2-PMPA reduces rewarding effects of the synthetic cathinone MDPV in rats: a role for N-acetylaspartylglutamate (NAAG).
Hicks C; Gregg RA; Nayak SU; Cannella LA; Schena GJ; Tallarida CS; Reitz AB; Smith GR; Rawls SM
Psychopharmacology (Berl); 2017 Jun; 234(11):1671-1681. PubMed ID: 28251297
[TBL] [Abstract][Full Text] [Related]
6. Effects of NAAG peptidase inhibitor 2-PMPA in model chronic pain - relation to brain concentration.
Nagel J; Belozertseva I; Greco S; Kashkin V; Malyshkin A; Jirgensons A; Shekunova E; Eilbacher B; Bespalov A; Danysz W
Neuropharmacology; 2006 Dec; 51(7-8):1163-71. PubMed ID: 16926034
[TBL] [Abstract][Full Text] [Related]
7. Effects of selective inhibition of N-acetylated-alpha-linked-acidic dipeptidase (NAALADase) on mice in learning and memory tasks.
Lukawski K; Kamiński RM; Czuczwar SJ
Eur J Pharmacol; 2008 Jan; 579(1-3):202-7. PubMed ID: 18031726
[TBL] [Abstract][Full Text] [Related]
8. 2-phosphonomethyl-pentanedioic acid (glutamate carboxypeptidase II inhibitor) increases threshold for electroconvulsions and enhances the antiseizure action of valproate against maximal electroshock-induced seizures in mice.
Luszczki JJ; Mohamed M; Czuczwar SJ
Eur J Pharmacol; 2006 Feb; 531(1-3):66-73. PubMed ID: 16403497
[TBL] [Abstract][Full Text] [Related]
9. Deletion of the glutamate carboxypeptidase II gene in mice reveals a second enzyme activity that hydrolyzes N-acetylaspartylglutamate.
Bacich DJ; Ramadan E; O'Keefe DS; Bukhari N; Wegorzewska I; Ojeifo O; Olszewski R; Wrenn CC; Bzdega T; Wroblewska B; Heston WD; Neale JH
J Neurochem; 2002 Oct; 83(1):20-9. PubMed ID: 12358725
[TBL] [Abstract][Full Text] [Related]
10. Establishment and characterization of an optimized mouse model of multiple sclerosis-induced neuropathic pain using behavioral, pharmacologic, histologic and immunohistochemical methods.
Khan N; Woodruff TM; Smith MT
Pharmacol Biochem Behav; 2014 Nov; 126():13-27. PubMed ID: 25223977
[TBL] [Abstract][Full Text] [Related]
11. NAAG peptidase inhibitors block cognitive deficit induced by MK-801 and motor activation induced by d-amphetamine in animal models of schizophrenia.
Olszewski RT; Janczura KJ; Ball SR; Madore JC; Lavin KM; Lee JC; Lee MJ; Der EK; Hark TJ; Farago PR; Profaci CP; Bzdega T; Neale JH
Transl Psychiatry; 2012 Jul; 2(7):e145. PubMed ID: 22850437
[TBL] [Abstract][Full Text] [Related]
12. Local enema treatment to inhibit FOLH1/GCPII as a novel therapy for inflammatory bowel disease.
Date AA; Rais R; Babu T; Ortiz J; Kanvinde P; Thomas AG; Zimmermann SC; Gadiano AJ; Halpert G; Slusher BS; Ensign LM
J Control Release; 2017 Oct; 263():132-138. PubMed ID: 28159515
[TBL] [Abstract][Full Text] [Related]
13. Molecular modeling of the interactions of glutamate carboxypeptidase II with its potent NAAG-based inhibitors.
Rong SB; Zhang J; Neale JH; Wroblewski JT; Wang S; Kozikowski AP
J Med Chem; 2002 Sep; 45(19):4140-52. PubMed ID: 12213057
[TBL] [Abstract][Full Text] [Related]
14. Glutamine antagonism attenuates physical and cognitive deficits in a model of MS.
Hollinger KR; Smith MD; Kirby LA; Prchalova E; Alt J; Rais R; Calabresi PA; Slusher BS
Neurol Neuroimmunol Neuroinflamm; 2019 Nov; 6(6):. PubMed ID: 31467038
[TBL] [Abstract][Full Text] [Related]
15. Changes in nociceptive sensitivity and object recognition in experimental autoimmune encephalomyelitis (EAE).
Olechowski CJ; Tenorio G; Sauve Y; Kerr BJ
Exp Neurol; 2013 Mar; 241():113-21. PubMed ID: 23291347
[TBL] [Abstract][Full Text] [Related]
16. Regulation of glutamate carboxypeptidase II hydrolysis of N-acetylaspartylglutamate (NAAG) in crayfish nervous tissue is mediated by glial glutamate and acetylcholine receptors.
Urazaev AK; Grossfeld RM; Lieberman EM
J Neurochem; 2005 May; 93(3):605-10. PubMed ID: 15836619
[TBL] [Abstract][Full Text] [Related]
17. High dose of dexamethasone protects against EAE-induced motor deficits but impairs learning/memory in C57BL/6 mice.
Dos Santos N; Novaes LS; Dragunas G; Rodrigues JR; Brandão W; Camarini R; Peron JPS; Munhoz CD
Sci Rep; 2019 Apr; 9(1):6673. PubMed ID: 31040362
[TBL] [Abstract][Full Text] [Related]
18. Still NAAG'ing After All These Years: The Continuing Pursuit of GCPII Inhibitors.
Vornov JJ; Hollinger KR; Jackson PF; Wozniak KM; Farah MH; Majer P; Rais R; Slusher BS
Adv Pharmacol; 2016; 76():215-55. PubMed ID: 27288079
[TBL] [Abstract][Full Text] [Related]
19. S1 pocket of glutamate carboxypeptidase II: a new binding site for amyloid-β degradation.
Lee SK; Kim H; Cheong YH; Kim MJ; Jo SA; Youn HS; Park SI
Biochem Biophys Res Commun; 2013 Sep; 438(4):765-71. PubMed ID: 23891752
[TBL] [Abstract][Full Text] [Related]
20. Enhanced Brain Delivery of 2-(Phosphonomethyl)pentanedioic Acid Following Intranasal Administration of Its γ-Substituted Ester Prodrugs.
Nedelcovych M; Dash RP; Tenora L; Zimmermann SC; Gadiano AJ; Garrett C; Alt J; Hollinger KR; Pommier E; Jančařík A; Rojas C; Thomas AG; Wu Y; Wozniak K; Majer P; Slusher BS; Rais R
Mol Pharm; 2017 Oct; 14(10):3248-3257. PubMed ID: 28763226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
